PRECLINICAL STUDIES FOR THE DEVELOPMENT OF INNOVATIVE TREATMENTS FOR ACUTE LYMPHOBLASTIC LEUKEMIA

Preclinical development

Targeted therapy
Chemotherapy

Preclinical research (TRL 4-5)

Preclinical studies for the development of innovative treatments for acute lymphoblastic leukemia (ALL), to assess the impact of drug candidates on leukemia cells and the development of normal T and B lymphocytes.

The models developed accurately represent the biology and heterogeneity of different types of leukemia and summarize the tumor microenvironment.

Description

Scope of research activities

Preclinical research using in vitro and in vivo models to assess the efficacy and toxicity (pre-regulatory) of new molecules:

Monitoring the development of human T and B lymphocytes during normal and pathological hematopoiesis

Conduct of studies

Steps:

Analysis of innovative product development strategy
Study design
Drafting of study plans
Establishment of quotes to finance the study
Organization, implementation and conduct of studies
Analysis and communication of results

Research infrastructure

Experimental and analytical platforms:

Flow cytometry
Animal experimentation (dedicated staff)
Animal facility
Molecular bioengineering
Microscopy
Ex-vivo screening of biomolecules

Preclinical models:

Immunodeficient mouse model of normal human hematopoiesis
Mouse model of human leukemia
T-ALL (including pediatric models) and B-ALL PDX

Specifications

The platform

Set of in vivo and in vitro tests for the evaluation and selection of drug candidates for the treatment of ALL.

The studies

Toxicity assessment on T lymphocyte development in immunodeficient mice:

Human T cell development in mouse thymus: monitoring by flow cytometry

Evaluation of drug candidate toxicity in mouse models of normal human cell xenografts:

Normal human hematopoietic development in vivo in the bone marrow of immunodeficient mice

Evaluation of drug candidate efficacy in PDX models of T-ALL and B-ALL:

Monitoring of leukemic growth in vitro; development of screening molecules

Evaluation of efficacy of drug candidates in PDX models of T-ALL and B-ALL in immunodeficient mice:

In vivo leukemic growth; development of molecule testing

Examples of partnerships

Study of the functionality of the ProTcell product in the regeneration of functional human T lymphocytes after treatment with chemotherapy or irradiation - The aim is to test the ability of the ProTcellR cell product, developed by Smart-Immune, to generate normal, functional human T cells in vivo in young and elderly immunodeficient mouse models.

Partner: Smart Immune

Terms

OPALE entity

UMR - 1274

**Dr. Françoise Pflumio**
Head of Entity

Contact

Other offers

PRECLINICAL STUDY OF HEMATOPOIETIC SYSTEM REGENERATION FOLLOWING EXPOSURE TO GENOTOXIC STRESS SUCH AS IRRADIATION AND CHEMOTHERAPY (ALL/AML)

PRECLINICAL TESTING OF CAR-T CELLS FOR THE TREATMENT OF T/B ACUTE LYMPHOBLASTIC LEUKEMIA